UPCC 10519 / I5B-MC-Y001: An Open-Label Multi-Center Patient Access Program of Olaratumab for the Treatment of Soft Tissue Sarcoma

The purpose of this program is to allow patients who, in consultation with their treating physician, feel it is in their best interest to continue to receive olaratumab. Only patients with soft tissue sarcoma who are already being treated with olaratumab may enter this program.

You may be eligible for this study if you meet the following criteria:

• Conditions:
  oncology, sarcoma
• Age: - 99 Years
• Gender: All